Sana Biotechnology Stock Current Liabilities
| SANA Stock | USD 2.61 0.26 11.06% |
Sana Biotechnology fundamentals help investors to digest information that contributes to Sana Biotechnology's financial success or failures. It also enables traders to predict the movement of Sana Stock. The fundamental analysis module provides a way to measure Sana Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sana Biotechnology stock.
At present, Sana Biotechnology's Non Current Liabilities Total is projected to increase significantly based on the last few years of reporting. The current year's Non Current Liabilities Other is expected to grow to about 166.8 M, whereas Total Current Liabilities is forecasted to decline to about 60.2 M. Sana | Current Liabilities |
Sana Biotechnology Company Current Liabilities Analysis
Sana Biotechnology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Sana Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Sana Biotechnology is extremely important. It helps to project a fair market value of Sana Stock properly, considering its historical fundamentals such as Current Liabilities. Since Sana Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sana Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sana Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Sana Current Liabilities Historical Pattern
Today, most investors in Sana Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sana Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sana Biotechnology current liabilities as a starting point in their analysis.
Sana Biotechnology Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Sana Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Sana Biotechnology has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Sana Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sana Biotechnology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sana Biotechnology could also be used in its relative valuation, which is a method of valuing Sana Biotechnology by comparing valuation metrics of similar companies.Sana Biotechnology is currently under evaluation in current liabilities category among its peers.
Sana Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sana Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sana Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Sana Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 479.81 M | ||||
| Shares Outstanding | 223.27 M | ||||
| Shares Owned By Insiders | 8.63 % | ||||
| Shares Owned By Institutions | 92.40 % | ||||
| Number Of Shares Shorted | 34.28 M | ||||
| Price To Book | 1.99 X | ||||
| EBITDA | (252.39 M) | ||||
| Net Income | (283.25 M) | ||||
| Cash And Equivalents | 484.8 M | ||||
| Cash Per Share | 2.57 X | ||||
| Total Debt | 104.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 5.09 X | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (253.58 M) | ||||
| Short Ratio | 32.61 X | ||||
| Earnings Per Share | (1.40) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 328 | ||||
| Beta | 1.44 | ||||
| Market Capitalization | 582.73 M | ||||
| Total Asset | 565.3 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 149.03 M | ||||
| Net Asset | 565.3 M |
About Sana Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sana Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sana Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sana Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out Sana Biotechnology Piotroski F Score and Sana Biotechnology Altman Z Score analysis. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.